Safety Follow-up Study of Inhaled Iloprost in Patients With Pulmonary Hypertension

Bayer71 enrolled

Overview

The aim of this study is to monitor long-term safety and tolerability of iloprost aerosol inhalation therapy in patients suffering from pulmonary hypertension.

This study has previously been posted by Schering AG, Germany. Schering AG has been renamed to Bayer Schering Pharma AG, Germany. Bayer Schering Pharma AG, Germany is the sponsor of the trial.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Hypertension, Pulmonary

Interventions

Ventavis (Iloprost, BAYQ6256)DRUG

Inhaled iloprost

Eligibility

Sex: ALLMin age: 18 YearsMax age: 71 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Completion of the 12-week treatment period of the predecessor Schering study 97218/300180 * Investigator judged iloprost aerosol therapy warranted as a suitable treatment for the respective patient * Negative pregnancy test for females Exclusion Criteria: * Any condition during 12-week treatment period of the predecessor Schering study 97218/300180 that prevents participation in the follow-up safety surveillance study

Locations (16)

Unnamed facility

Brussels, Belgium

Unnamed facility

Leuven, Belgium

Unnamed facility

Clamart, France

Unnamed facility

Outcomes

Primary Outcomes

Adverse events

Time frame: Throughout the whole study

Secondary Outcomes

Tolerability of treatment

Time frame: Over a minimum of 24 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.